Literature DB >> 29719554

Pipeline Flex Embolization of Flow-Related Aneurysms Associated with Arteriovenous Malformations: A Case Report.

Narlin B Beaty1, Jessica K Campos1, Geoffrey P Colby2, Li-Mei Lin3, Matthew T Bender1, Risheng Xu1, Alexander L Coon1.   

Abstract

BACKGROUND: An estimated 0.1% of the population harbors brain arteriovenous malformations (AVMs). Diagnosis and workup of AVMs include thorough evaluation for characterization of AVM angioarchitecture and careful assessment for concomitant aneurysms. The presence of coexisting aneurysms is associated with an increased risk of intracranial hemorrhage, with a published risk of 7% per year compared to patients with AVMs alone with a risk of 3%. Comprehensive AVM management requires recognition of concomitant aneurysms and prioritizes treatment strategies to mitigate the aggregate risk of intracranial hemorrhage associated with AVM rupture in patients with coexisting aneurysms. Endovascular treatment of these flow-related aneurysms can offer a cure, while avoiding open surgery. Successful flow-diverting embolization techniques, efficacy, and outcomes have been previously described for a variety of aneurysm types and locations. However, use of a flow diverter has not been previously described for the treatment of high-flow aneurysms on AVM-feeding vessels. CASE
PRESENTATION: We report 2 cases of large AVMs within eloquent cortex associated with flow-related aneurysms in patients presenting initially with suspected intracerebral hemorrhage secondary to AVM rupture. DISCUSSION: No consensus currently exists to guide treatment of intracranial aneurysms associated with AVMs. Surgical management addressed AVM embolization initially, as the vasculopathology with the highest rupture risk. Subsequently, Pipeline embolization of the associated aneurysms with adequate antiplatelet treatment was performed before scheduled radiosurgery to decrease the risk of AVM rupture or rebleed. This represents a novel and promising use of the Pipeline Embolization Device. Additional cases and longer follow-up will be needed to further assess the efficacy of this technique.

Entities:  

Keywords:  Cerebral arteriovenous malformations; Endovascular management strategies; Flow diversion embolization; Flow-related aneurysm; Pipeline Flex Embolization Device

Year:  2018        PMID: 29719554      PMCID: PMC5921187          DOI: 10.1159/000484986

Source DB:  PubMed          Journal:  Interv Neurol        ISSN: 1664-5545


  29 in total

1.  Long-Term Clinical and Angiographic Outcomes Following Pipeline Embolization Device Treatment of Complex Internal Carotid Artery Aneurysms: Five-Year Results of the Pipeline for Uncoilable or Failed Aneurysms Trial.

Authors:  Tibor Becske; Waleed Brinjikji; Matthew B Potts; David F Kallmes; Maksim Shapiro; Christopher J Moran; Elad I Levy; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Henry H Woo; Demetrius K Lopes; Adnan H Siddiqui; Felipe C Albuquerque; David J Fiorella; Isil Saatci; Saruhan H Cekirge; Aaron L Berez; Daniel J Cher; Zsolt Berentei; Miklós Marosfoi; Peter K Nelson
Journal:  Neurosurgery       Date:  2017-01-01       Impact factor: 4.654

2.  The AVICH Score: A Novel Grading System to Predict Clinical Outcome in Arteriovenous Malformation-Related Intracerebral Hemorrhage.

Authors:  Marian C Neidert; Michael T Lawton; Marius Mader; Burkhardt Seifert; Antonios Valavanis; Luca Regli; Oliver Bozinov; Jan-Karl Burkhardt
Journal:  World Neurosurg       Date:  2016-05-02       Impact factor: 2.104

3.  The natural history of AVM hemorrhage in the posterior fossa: comparison of hematoma volumes and neurological outcomes in patients with ruptured infra- and supratentorial AVMs.

Authors:  Adib A Abla; Jeffrey Nelson; W Caleb Rutledge; William L Young; Helen Kim; Michael T Lawton
Journal:  Neurosurg Focus       Date:  2014-09       Impact factor: 4.047

4.  The management of patients with arteriovenous malformations and associated intracranial aneurysms.

Authors:  R C Thompson; G K Steinberg; R P Levy; M P Marks
Journal:  Neurosurgery       Date:  1998-08       Impact factor: 4.654

5.  Frequency of intracranial hemorrhage as a presenting symptom and subtype analysis: a population-based study of intracranial vascular malformations in Olmsted Country, Minnesota.

Authors:  R D Brown; D O Wiebers; J C Torner; W M O'Fallon
Journal:  J Neurosurg       Date:  1996-07       Impact factor: 5.115

6.  Concurrent arterial aneurysms in brain arteriovenous malformations with haemorrhagic presentation.

Authors:  C Stapf; J P Mohr; J Pile-Spellman; R R Sciacca; A Hartmann; H C Schumacher; H Mast
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

7.  Utilization of the Navien distal intracranial catheter in 78 cases of anterior circulation aneurysm treatment with the Pipeline embolization device.

Authors:  Geoffrey P Colby; Li-Mei Lin; Judy Huang; Rafael J Tamargo; Alexander L Coon
Journal:  J Neurointerv Surg       Date:  2013-03-20       Impact factor: 5.836

8.  Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage.

Authors:  Robert W V Flynn; Thomas M MacDonald; Gordon D Murray; Ronald S MacWalter; Alexander S F Doney
Journal:  Stroke       Date:  2010-10-14       Impact factor: 7.914

9.  Antiplatelet therapy may be continued after intracerebral hemorrhage.

Authors:  Rustam Al-Shahi Salman; Martin S Dennis
Journal:  Stroke       Date:  2014-09-09       Impact factor: 7.914

10.  Variation in restarting antithrombotic drugs at hospital discharge after intracerebral hemorrhage.

Authors:  Marta Pasquini; Andreas Charidimou; Charlotte J J van Asch; Merih I Baharoglu; Neshika Samarasekera; David J Werring; Catharina J M Klijn; Yvo B Roos; Rustam Al-Shahi Salman; Charlotte Cordonnier
Journal:  Stroke       Date:  2014-07-31       Impact factor: 7.914

View more
  1 in total

Review 1.  Endovascular Treatment of Posterior Cerebral Artery Trunk Aneurysm: The Status Quo and Dilemma.

Authors:  Kun Hou; Xianli Lv; Jinlu Yu
Journal:  Front Neurol       Date:  2022-01-06       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.